S2 Table. Joinpoint regression analysis for cutaneous melanoma, squamous cell carcinoma, and basal cell carcinoma by sex and age group

| Category | Trend 1 |  | Trend 2 |  | Trend 3 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Year | APC (95\% CI, \%) | Year | APC (95\% CI, \%) | Year | APC (95\% CI, \%) |
| Men |  |  |  |  |  |  |
| Cutaneous melanoma | 1999-2005 | 7.9 (2.4 to 13.7)* | 2005-2014 | -0.2 (-2.3 to 2.0) | - | - |
| $<40 \mathrm{yr}$ | 1999-2014 | 3.7 (-0.3 to 7.9) | - | - | - | - |
| $40-59 \mathrm{yr}$ | 1999-2014 | 1.5 (-0.1 to 3.0) | - | - | - | - |
| $60-79 \mathrm{yr}$ | 1999-2014 | 1.6 (-0.6 to 4.0) | - | - | - | - |
| $\geq 80 \mathrm{yr}$ | 1999-2014 | 5.0 (0.8 to 9.3)* | - | - | - | - |
| Squamous cell carcinoma | 1999-2014 | 3.3 (2.6 to 4.0)* | - | - | - | - |
| $<40 \mathrm{yr}$ | 1999-2014 | -0.1 (-4.2 to 4.1) | - | - | - | - |
| $40-59 \mathrm{yr}$ | 1999-2014 | 1.7 (0.3 to 3.1)* | - | - | - | - |
| $60-79 \mathrm{yr}$ | 1999-2014 | 2.9 (2.1 to 3.8)* | - | - | - | - |
| $\geq 80 \mathrm{yr}$ | 1999-2014 | 6.2 (4.0 to 8.4)* | - | - | - | - |
| Basal cell carcinoma | 1999-2007 | 11.3 (7.6 to 15.1$)^{*}$ | 2007-2014 | 4.4 (1.9 to 7.0)* | - | - |
| $<40 \mathrm{yr}$ | 1999-2014 | 9.3 (6.1 to 12.5)* | - | - | - | - |
| $40-59 \mathrm{yr}$ | 1999-2014 | 6.3 (4.8 to 7.8)* | - | - | - | ${ }^{-}{ }^{-}$ |
| $60-79 \mathrm{yr}$ | 1999-2004 | 4.4 (-3.8 to 13.3) | 2004-2007 | 19.1 (-8.8 to 55.4) | 2007-2014 | 2.8 (0.1 to 5.5)* |
| $\geq 80 \mathrm{yr}$ | 1999-2014 | 10.7 (8.3 to 13.1)* | - | - | - | - |
| Women |  |  |  |  |  |  |
| Cutaneous melanoma | 1999-2014 | 3.5 (2.4 to 4.6)* | - | - | - | - |
| $<40 \mathrm{yr}$ | 1999-2014 | 3.7 (-0.5 to 8.1)* | - | - | - | - |
| $40-59 \mathrm{yr}$ | 1999-2014 | 2.0 (0.4 to 3.5)****** | - | - | - | - |
| $60-79 \mathrm{yr}$ | 1999-2014 | 3.8 (2.4 to 5.2)****** | - | - | - | - |
| $\geq 80 \mathrm{yr}$ | 1999-2014 | 8.1 (5.1 to 11.2)* | - |  | - | - |
| Squamous cell carcinoma | 1999-2007 | 9.4 (6.7 to 12.3)* | 2007-2014 | 3.9 (1.9 to 6.0)* | - | - |
| $<40 \mathrm{yr}$ | 1999-2014 | 2.4 ( -2.5 to 7.6 ) | - |  | - | - |
| $40-59 \mathrm{yr}$ | 1999-2014 | 2.1 (0.0 to 4.2)****** | - | - | - | - |
| $60-79 \mathrm{yr}$ | 1999-2014 | 4.9 (3.6 to 6.2)* | - | - | - | - |
| $\geq 80 \mathrm{yr}$ | 1999-2006 | 17.1 (11.3 to 23.2)* | 2006-2014 | 7.2 (5.1 to 9.3)* | - | - |
| Basal cell carcinoma | 1999-2007 | 13.4 (10.7 to 16.1)** | 2007-2014 | 4.1 (2.3 to 6.0)* | - | - |
| $<40 \mathrm{yr}$ | 1999-2014 | 6.5 (2.9 to 10.2)* | - | - | - | - |
| $40-59 \mathrm{yr}$ | 1999-2014 | 6.2 (4.3 to 8.1)* | - | - ${ }^{-}$ | - | - |
| $60-79 \mathrm{yr}$ | 1999-2006 | 14.9 (11.9 to 17.9)* | 2006-2014 | 4.4 (3.1 to 5.8)* | - | - |
| $\geq 80 \mathrm{yr}$ | 1999-2011 | 15.2 (12.3 to 18.1)** | 2011-2014 | -0.4 (-10.0 to 10.3) | - | - |

The unit for APC was expressed as \% change per year. The age-standardized incidence rates are presented as cases per 100,000 people, using Segi's world standard population as the standard population. Joinpoint regression analysis was used to determine whether there were significant changes in trends in age-standardized incidence rates for the period between 1999 and 2014. APC, annual percent change; CI, confidence interval. ${ }^{\text {p }}<0.05$.

